{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Fernando J. Sialana"}, {"accession": "MS:1000589", "name": "contact email", "value": "fsialana@yahoo.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Pharmaceutical Chemistry, University of Vienna"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Gert Lubec"}, {"accession": "MS:1000589", "name": "contact email", "value": "gert.lubec@lubeclab.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "University of Vienna"}]}], "datasetFiles": [{"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc20-BA1-P1122-3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc20-BA1-P1122-4.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc20-BA2-P1123-3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc20-BA2-P1123-4.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc21-BA3-P1124-3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc21-BA3-P1124-4.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc21-BA4-P1125-3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/MP02-THc21-BA4-P1125-4.raw"}, {"accession": "PRIDE:0000408", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/txt.zip"}, {"accession": "PRIDE:0000410", "name": "'Other' type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/experimentalDesignTemplate.txt"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244/andromeda.zip"}], "description": "Dendritic cell (DC)-based immunotherapy against glioblastoma multiforme is a novel treatment hope. Glioblastoma stem-like cells are, however, potentially causing immunoresistance. Glioblastoma cells cultured as gliomaspheres show a stem-like phenotype as opposed to classical adherent culture. They are thus a promising antigen source to specifically target glioblastoma stem-like cells via DC therapy and so overcome immunoresistance. Here we study the importance of gliomasphere-specific. Methodologically, we used 7 gliomaspheres, 3 of them patient-derived, as model system. Gliomasphere-specific protein expression was explored via quantitative proteomics.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/04/PXD008244"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD008244"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD008244"}], "instruments": [{"accession": "MS:1002634", "name": "Q Exactive Plus"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Glioblastoma multiforme, dendritic cell, immunotherapy, gliomasphere, antigen source, quantitative proteomics"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "30975602"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "Erhart F, Weiss T, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Blauensteiner B, L\u00f6tsch D, Spiegl-Kreinecker S, Berger W, Sialana FJ, Lubec G, Felzmann T, Dohnal A, Visus C. Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon \u03b3 production. Cytotherapy. 2019"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Adherent and Spheroid Glioblastoma Proteomics"}